CEO and Managing Director, Tim Oldham, was lead author on a poster describing AdAlta's unique "East to West" cellular immunotherapy business model that was presented at ISCTANZ2026 in Melbourne. The poster was upgraded to an oral presentation, recognising the opportunity AdAlta's strategy has to bring new hope to patients with solid cancers, including advanced mesothelioma patients where AdAlta's EW-001 armoured CAR-T product is the only product that has demonstrated complete responses in a patient population with median survival less than one year.